Eiger BioPharmaceuticals, Inc.

NasdaqGM:EIGR Stock Report

Market Cap: US$8.3m

Eiger BioPharmaceuticals Past Earnings Performance

Past criteria checks 0/6

Eiger BioPharmaceuticals's earnings have been declining at an average annual rate of -10.9%, while the Biotechs industry saw earnings growing at 14.5% annually. Revenues have been growing at an average rate of 64.7% per year.

Key information

-10.9%

Earnings growth rate

16.5%

EPS growth rate

Biotechs Industry Growth17.0%
Revenue growth rate64.7%
Return on equityn/a
Net Margin-590.8%
Last Earnings Update30 Sep 2023

Recent past performance updates

Recent updates

The Market Doesn't Like What It Sees From Eiger BioPharmaceuticals, Inc.'s (NASDAQ:EIGR) Revenues Yet As Shares Tumble 26%

Jan 04
The Market Doesn't Like What It Sees From Eiger BioPharmaceuticals, Inc.'s (NASDAQ:EIGR) Revenues Yet As Shares Tumble 26%

Analysts Have Just Cut Their Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) Revenue Estimates By 22%

Dec 20
Analysts Have Just Cut Their Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) Revenue Estimates By 22%

Analyst Forecasts For Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) Are Surging Higher

Nov 09
Analyst Forecasts For Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) Are Surging Higher

Rock star Growth Puts Eiger BioPharmaceuticals (NASDAQ:EIGR) In A Position To Use Debt

Oct 06
Rock star Growth Puts Eiger BioPharmaceuticals (NASDAQ:EIGR) In A Position To Use Debt

Eiger sheds ~20% on abandonment of EUA request for COVID therapy

Oct 05

Eiger falls 21% amid uncertainty over regulatory path for COVID-19 therapy

Sep 06

Eiger BioPharmaceuticals: Undervalued Biotech With End Of 2022 Catalyst

Jul 26

European Commission approves Eiger BioPharmaceuticals' progeria therapy Zokinvy

Jul 20

Eiger Biopharmaceuticals: Value Inflection For Lead Asset In HDV Infection On The Horizon

Apr 06

Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) Analysts Are More Bearish Than They Used To Be

Mar 15
Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) Analysts Are More Bearish Than They Used To Be

Eiger Pharma: HDV Approval In 2023 Is A Major Catalyst

Dec 26

Does Eiger BioPharmaceuticals (NASDAQ:EIGR) Have A Healthy Balance Sheet?

Jun 03
Does Eiger BioPharmaceuticals (NASDAQ:EIGR) Have A Healthy Balance Sheet?

Eiger BioPharmaceuticals Investor Presentation - Slideshow

May 08

Have Insiders Been Buying Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) Shares This Year?

Mar 16
Have Insiders Been Buying Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) Shares This Year?

What Type Of Shareholders Own The Most Number of Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) Shares?

Jan 22
What Type Of Shareholders Own The Most Number of Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) Shares?

Eiger targets Zokinvy EMA approval and late-stage trial initiation for Lambda in 2021

Jan 07

Have Insiders Been Buying Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) Shares?

Dec 01
Have Insiders Been Buying Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) Shares?

Eiger Looks Like A Solid Long-Term Play After Zokinvy's Approval

Nov 30

Eiger Bio rises 8% on sale of priority review voucher for $95M

Nov 23

FDA OK's Eiger BioPharma's Hutchinson-Gilford treatment

Nov 21

Revenue & Expenses Breakdown
Beta

How Eiger BioPharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NasdaqGM:EIGR Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 2315-872969
30 Jun 2315-963077
31 Mar 2315-973274
31 Dec 2213-972975
30 Sep 2214-932775
30 Jun 2213-892671
31 Mar 2211-862568
31 Dec 2112-342464
30 Sep 219-312359
30 Jun 216-242250
31 Mar 214-212146
31 Dec 200-652142
30 Sep 200-632041
30 Jun 200-661945
31 Mar 200-681848
31 Dec 190-701752
30 Sep 190-701752
30 Jun 190-681651
31 Mar 190-611544
31 Dec 180-521437
30 Sep 180-471333
30 Jun 180-391226
31 Mar 180-401128
31 Dec 170-421230
30 Sep 170-441331
30 Jun 170-471333
31 Mar 170-491336
31 Dec 160-471333
30 Sep 160-411327
30 Jun 160-331021
31 Mar 160-22813
31 Dec 150-1358
30 Sep 150-725
31 Dec 140-211

Quality Earnings: EIGR is currently unprofitable.

Growing Profit Margin: EIGR is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: EIGR is unprofitable, and losses have increased over the past 5 years at a rate of 10.9% per year.

Accelerating Growth: Unable to compare EIGR's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: EIGR is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-8.9%).


Return on Equity

High ROE: EIGR's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.